Trial · NCT00481845
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
NCT00481845, Phase 2, Terminated, Stanford University; results first posted 2017-02-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer. Trials, record NCT00481845. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00481845
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
- NCT number
- NCT00481845
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Breast Cancer
- Interventions
- Vandetanib, Anastrozole
- First posted
- 2007-06-04
- Last updated
- 2017-02-07
- Results first posted
- 2017-02-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor Objective Response by MRI | 1 year | Determine tumor objective response rate by MRI. (CR): Disappearance of the target lesion (PR): At least a 30% decrease in the longest diameter of the target lesion taking as reference the baseline LD (PD): At least a 20% increase in the LD of target lesion, taking as reference the baseline LD or the appearance of one or more new lesions (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the baseline LD. |
| Secondary | Pathologic Complete Response | 1 year |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Tumor Objective Response by MRI | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Pathologic Complete Response | 1 year | CR+PR | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tumor Objective Response by MRI | Vandetanib + Anastrozole | Complete Response- CR | 0 | Participants | |
| Tumor Objective Response by MRI | Anastrozole | Complete Response- CR | 0 | Participants | |
| Tumor Objective Response by MRI | Vandetanib + Anastrozole | Partial Response- PR | 0 | Participants | |
| Tumor Objective Response by MRI | Anastrozole | Partial Response- PR | 0 | Participants | |
| Tumor Objective Response by MRI | Vandetanib + Anastrozole | Progressive Disease- PD | 0 | Participants | |
| Tumor Objective Response by MRI | Anastrozole | Progressive Disease- PD | 0 | Participants | |
| Tumor Objective Response by MRI | Vandetanib + Anastrozole | Stable Disease-SD | 1 | Participants | |
| Tumor Objective Response by MRI | Anastrozole | Stable Disease-SD | 0 | Participants | |
| Pathologic Complete Response | Vandetanib + Anastrozole | 0 | Participants | ||
| Pathologic Complete Response | Anastrozole | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Vandetanib + Anastrozole | 1 | |
| Overall Study | STARTED | Anastrozole | 0 | |
| Overall Study | COMPLETED | Vandetanib + Anastrozole | 1 | |
| Overall Study | COMPLETED | Anastrozole | 0 | |
| Overall Study | NOT COMPLETED | Vandetanib + Anastrozole | 0 | |
| Overall Study | NOT COMPLETED | Anastrozole | 0 |
Source ClinicalTrials.gov
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vague chest discomfort | Cardiac disorders | Vandetanib + Anastrozole | 1 | 1 | 2 |
| other | Vague chest discomfort | Cardiac disorders | Anastrozole | 0 | 0 | 0 |
| other | Sweaty palms | Nervous system disorders | Vandetanib + Anastrozole | 1 | 1 | 1 |
| other | Sweaty palms | Nervous system disorders | Anastrozole | 0 | 0 | 0 |
| other | Painic attack | Nervous system disorders | Vandetanib + Anastrozole | 1 | 1 | 1 |
| other | Painic attack | Nervous system disorders | Anastrozole | 0 | 0 | 0 |
| other | Constipation | Gastrointestinal disorders | Vandetanib + Anastrozole | 1 | 1 | 1 |
| other | Constipation | Gastrointestinal disorders | Anastrozole | 0 | 0 | 0 |
| other | increasing reflux symptoms | Gastrointestinal disorders | Vandetanib + Anastrozole | 1 | 1 | 1 |
| other | increasing reflux symptoms | Gastrointestinal disorders | Anastrozole | 0 | 0 | 0 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Vandetanib + Anastrozole | ||
| Total, all-cause mortality | Anastrozole | ||
| Total, other adverse events | Vandetanib + Anastrozole | 1 | 1 |
| Total, other adverse events | Anastrozole | 0 | 0 |
| Total, serious adverse events | Vandetanib + Anastrozole | 1 | 1 |
| Total, serious adverse events | Anastrozole | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00481845
GET https://conductscience.org/api/trials/v1/NCT00481845/registered